Clinical trial
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells…
NCT00465985 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00465985 |
|---|---|
| Title | Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome |
| Official title | A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome |
| Acronym | REMITTER |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Muckle Wells Syndrome |
| Intervention type | Drug |
| Interventions | ACZ885, Placebo |
| Enrollment | 35 |
| Start date | Apr 1, 2007 |
| Primary completion | Oct 1, 2008 |
| First posted | Apr 27, 2007 |
| Last update posted | Aug 28, 2017 |
| Countries | France, Germany, India, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: